How mRNA Technology is Revolutionising Medicine Beyond Vaccines

mRNA technology, initially recognised for its groundbreaking role in COVID-19 vaccines, is now transforming medicine far beyond infectious diseases.

Unlike traditional therapies, mRNA acts as a messenger, instructing cells to produce specific proteins that trigger a therapeutic response. This platform has opened the door to a wide range of possibilities, from personalised cancer treatments to therapies for genetic disorders and autoimmune diseases.

Dr Daniel Getts is CEO of Myeloid Therapeutics, which has been selected by the NSW Government as the operator of the new RNA Research and Pilot Manufacturing Facility currently under construction at Macquarie University.

Daniel will explain how RNA technology is evolving and revolutionising how we approach treatments for a wide range of diseases, offering more precise, effective and adaptable solutions across various fields of medicine.

Join Daniel as he examines how mRNA’s potential is only just beginning to be realised, signalling a new era of therapeutic innovation.

Daniel is a leading figure in developing novel treatments for cancer and autoimmune diseases. An immunologist trained at the University of Sydney, Daniel is CEO and Co-Founder of Myeloid Therapeutics, a global leader in RNA therapeutics.

Daniel this year founded Aurora Biosynthetics Pty Ltd, in partnership with the NSW Government, focused on advancing DNA and RNA manufacturing in the burgeoning RNA Sydney ecosystem. Aurora Biosynthetics will operate the new $96 million RNA Research and Pilot Manufacturing Facility which has commenced construction at Macquarie University’s Wallumattagal Campus.

Daniel’s work has attracted over US$1 billion in private funding, resulting in the discovery and translation of nine innovative therapeutics.

He previously co-founded Cour Pharmaceuticals, where he contributed to the creation of TIMP-GLIA, a nanotherapy designed to induce gluten tolerance.

With over 50 peer-reviewed publications and more than 100 patents, Daniel has made significant contributions to immunology, cancer treatment and RNA-based therapies.

Host or Publisher Office of the NSW Chief Scientist & Engineer